A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.
Future Oncol
; 18(10): 1185-1198, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2065335
ABSTRACT
Cabozantinib inhibits multiple receptor tyrosine kinases, including the TAM kinase family, and may enhance response to immune checkpoint inhibitors. One cohort of the ongoing phase Ib COSMIC-021 study (NCT03170960) evaluating cabozantinib plus the PD-L1 inhibitor atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue on/after enzalutamide and/or abiraterone treatment for metastatic disease has shown promising efficacy. Here, we describe the rationale and design of a phase III trial of cabozantinib plus atezolizumab versus a second novel hormone therapy (NHT) in patients who have previously received an NHT for mCRPC, metastatic castration-sensitive PC or nonmetastatic CRPC and have measurable visceral disease and/or extrapelvic adenopathy - a population with a significant unmet need for treatment options. Trial Registration Clinical Trial Registration NCT04446117 (ClinicalTrials.gov) Registered on 24 June 2020.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Piridinas
/
Adenocarcinoma
/
Antineoplásicos Hormonales
/
Anticuerpos Monoclonales Humanizados
/
Neoplasias de la Próstata Resistentes a la Castración
/
Inhibidores de Puntos de Control Inmunológico
/
Anilidas
Tipo de estudio:
Estudio de cohorte
/
Estudio experimental
/
Estudio observacional
/
Estudio pronóstico
/
Ensayo controlado aleatorizado
Límite:
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Future Oncol
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
Fon-2021-1096
Similares
MEDLINE
...
LILACS
LIS